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The incidence of many neurodegenerative diseases, such as Parkin-
son's disease (PD), correlates well with gender [1]. Thus, PD occurs 1.5
times more frequently in men than in women [2–5]. In women, the age
of onset of PD correlates with the duration of the fertile life [6,7]. PD is a
progressive disorder characterized by a profound loss of dopaminergic
neurons in the mesencephalic substantia nigra pars compacta with a
marked depletion of striatal dopamine. The resulting striatal deﬁciency
leads to theparkinsonian syndromeof bradykinesia, rigidity, tremor, and
motor and postural instability [8,9]. Although the etiology of PD remains
unknown, an accumulating body of evidence in experimental models of
PD and in postmortem tissues of sporadic forms of PD suggests that
mitochondrial dysfunction due to an impairment of mitochondrial
energyproduction and subsequentoxidative stressmaybe involved. The
identiﬁcation of speciﬁc gene mutations and their inﬂuence on
mitochondrial functions has further emphasized the relevance of
mitochondrial abnormalities in the disease pathogenesis [10]. It is stillunderdebate if respiratory chaindeﬁciency is etiological in PD.However,
ample data strongly suggest that toxin-induced respiratory chain
disruption per se is sufﬁcient to trigger thedeath of nigrostriatal neurons
and to cause PD-like symptoms in animals and humans. Interestingly,
experimental models comprise the application of inhibitors of respira-
tory chain complex I, such as 6-OHDA (6-hydroxydopamine), MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) or its metabolized toxic
form MPP+ (N-methyl-4-phenylpyridinium ion), or rotenone. This
points at a speciﬁc role of complex I herein and further reinforces the role
of mitochondria in neurodegeneration. These complex I inhibitors and
neurotoxins inhibit ATP (adenosine 5’-triphosphate) synthesis in
mitochondria causing a loss of ATP and, moreover, stimulate reactive
oxygen species (ROS) production by mitochondria [11]. The selective
toxicity of 6-OHDA to dopaminergic neurons in the substantia nigra was
explained by the fact that 6-OHDA is selectively accumulated and
subsequently oxidized to produce hydrogen peroxide, superoxide, and
hydroxyl radicals in these cells [12,13]. Besides complex I, 6-OHDA has
been shown to also inhibit complex IV in vitro [14]. In vivo administration
of 6-OHDA causes a parkinsonian condition characterized by decreased
dopamine levels and tyrosine hydroxylase (TH) activity, impaired
dopamine uptake, and ensuing loss of dopaminergic neurons. Given
the parallels with PD, the mechanism by which this compound leads to
neuronal cells death is of great interest. The gender-speciﬁcity of 6-
OHDA-mediated effects has been demonstrated in a rat model, where
male rats were more susceptible to 6-OHDA than females showing
less dopaminergic cell loss and a higher degree of behavioral recovery
[15]. However, a gender-speciﬁc disturbance of mitochondrial function
and energy metabolism has not been demonstrated yet. Although
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the largest impairment of function and survival in PD and the
appropriate in vitro and in vivo model systems, this disorder involves
not only this particular cell type but also non-dopaminergic neurons
[16]. We therefore studied structural and functional characteristics of
mitochondria along with the survival of their dopaminergic and non-
dopaminergic neuronal hosts isolated from mouse brain mesencephali
as the brain region being most affected in PD.
2. Materials and methods
2.1. Materials
All chemicals were obtained from Roth (Karlsruhe, Germany),
whereas reagents for molecular biological techniques and cell culture
were purchased from Invitrogen (Karlsruhe, Germany), unless noted
otherwise.
2.2. Animals
BALB/c mice were purchased from Harlan Winkelmann GmbH
(Borchen, Germany). All procedures were performed in strict
accordance with the published welfare rules for the care and use of
laboratory animals at the University Clinic Aachen and the govern-
ment of the State of Nordrhein-Westfalen, Germany.
2.3. Preparation of primary mesencephalic neuron cultures
Primary neurons were prepared from mesencephali of BALB/c
mouse brains at gestation day 14/15 and cultured as described
previously with some modiﬁcations [17]. To distinguish between
male and female fetuses the gonadal anlage was inspected. At this age,
the testicular artery can be identiﬁed in a male fetus. The correctness
of determining anatomically the gender of the fetuses was conﬁrmed
for the neuronal cell populations by qRT-PCR checking for female-
(Xist) and male-speciﬁc (SRY) gene transcription. Brieﬂy, mice
embryos were taken from pregnant female mice after cervical
dislocation. Mesencephalic tissues were taken and meninges re-
moved. Subsequently, the tissue was mechanically dissociated and
digested in the presence of 0.1% (v/v) trypsin and 0.02% (w/v) EDTA
in PBS for 15 min at 37 °C. The suspension was supplemented with
20% (v/v) heat-inactivated fetal calf serum (FCS; PAA, Coelbe,
Germany) and DNase I (170 U/ml; Sigma-Aldrich, Munich, Germany),
triturated using a Pasteur pipette, and centrifuged for 5 min at 1000g.
Cells were resuspended in neurobasal medium (NBM) supplemented
with 0.4% (v/v) B27, 50 U/ml penicillin, 50 µg/ml streptomycin,
2 mM L-glutamine (Glutamax®), 10% (v/v) FCS and plated onto poly-
L-ornithine-coated (Sigma-Aldrich) culture dishes at a density of 1.5–
2.0×105 cells per cm2. Cell cultures were maintained at 37 °C in a
humidiﬁed atmosphere of 95% air/5% CO2. After 24 h, the cell medium
was deprived of FCS. This procedure typically yields neuron-enriched
cultures containing N90% neurons, of which ca. 2–3% were dopami-
nergic (TH-positive) cells, and b10% glial cells mostly astrocytes.
2.4. Cell treatment
Primary neuron cell cultures placed on culture dishes at 37 °C in a
humidiﬁed atmosphere of 95% air/5% CO2 in the presence of NBM
were treated with 25 µM and 50 µM 6-OHDA (Sigma-Aldrich) for
24 h. Cells of the same preparation maintained under the same
conditions except for 6-OHDA treatment served as controls. To study a
possible recovery of cell viability, neuron cultures were incubated for
additional 48 h post-toxin treatment in complete NBMmedium under
normal culturing conditions. Protective effects of 17β-estradiol (E;
Sigma-Aldrich) at a concentration of 10−7 M were studied by pre-
application for 3 h and/or co-application of E with 6-OHDA for 24 h.2.5. Fluorescence immunocytochemistry
Mesencephalon-derived primary neurons cultured on poly-L-
ornithine-coated coverslips (Menzel, Braunschweig, Germany) were
detected by immunocytochemical staining. First, nuclei of cells were
stained in the presence of 1 µg/ml Hoechst 33342 trihydrochloride
(Hoechst; Invitrogen, Eugene, Oregon, USA) for 15 min under
culturing conditions. After washing with phosphate buffered saline
(PBS), Hoechst-stained cells were ﬁxed with 4% (w/v) paraformalde-
hyde (Merck, Darmstadt, Germany) for 30 min at room temperature,
washed twice with PBS, and permeabilized with PBS containing 0.2%
(v/v) Triton X-100 (PBS-TX-100) for 15 min. Blocking was performed
in the presence of 3% (w/v) bovine serum albumin (BSA) in PBS for
20 min. Primary antibodies against tyrosine hydroxylase (TH; Abcam,
Cambridge, UK), NeuN (Chemicon, Temigula, CA, USA), active caspase
3 (Abcam), and neuroﬁlament SMI 311 and SMI 312 (Covance,
Berkeley, CA, USA) were diluted in 3% (w/v) BSA in PBS and incubated
with cells at 4 °C overnight. Subsequently, cells were washed three
times with PBS and incubated in the presence of the appropriate
secondary Alexa Fluor® 488- or Alexa Fluor® 594-labeled anti-mouse
or anti-rabbit antibodies for 2 h at room temperature. Cells were
washed with PBS three times for 5 min and mounted with Mowiol
(Fluka, Steinheim, Germany). Cells were examined using a ﬂuores-
cence Axiophot microscope (Carl Zeiss, Oberkochern, Germany)
equippedwith the softwareNIS-elements AR 3.0® (Nikon, Düsseldorf,
Germany) at excitation wavelengths of 365±12 nm (Hoechst), 450–
490 nm (Alexa Fluor® 488) and 530–585 nm (Alexa Fluor® 594) or
using a confocal LSM7DUOmicroscope (Carl Zeiss) equippedwith the
software ZEN 2009 at the appropriate laser wavelength to excite the
respective ﬂuorophors.
2.6. Cell viability, apoptosis and necrosis assays
2.6.1. Lactate dehydrogenase (LDH) activity assay
In order to estimate cell death, the level of lactate dehydrogenase
(LDH) released from damaged cells into culture media was measured
by detecting the enzyme activity at 24 h after treatmentwith 6-OHDA.
A colorimetric assay was applied. Themedium from cultured cells was
collected and incubated with the appropriate reagent mixture
according to the manufacturer's protocol (Cytotoxicity Detection Kit,
Roche, Mannheim, Germany) at room temperature for 30 min. The
red color of formazan salt formed during the incubation as a result of
tetrazolium salt reduction by LDH-mediated conversion of lactate to
pyruvate was measured at a wavelength of 490 nm. The measured
absorbance intensity is proportional to LDH activity and thereby to the
percentage of damaged cells. Data were normalized to LDH activity
released from Triton X-100-treated control cells set 100% of cell death.
2.6.2. Apoptosis and necrosis assays
To distinguish between apoptotic and necrotic neurons, 6-OHDA-
treated and untreated control cells were cultured on poly-L-ornithine
coated coverlips and stained with a combination of Hoechst 33342,
propidium iodide and active caspase 3. Cellswereﬁrst incubated in the
presence of 1 µg/ml Hoechst 33342 trihydrochloride (Hoechst;
Invitrogen) for 15 min under culturing conditions and subsequently
washed twice with PBS. Thereafter, cells were incubated in 2× SSC
buffer consisting of 0.3 M NaCl, 0.03 M sodium citrate, pH 7.0 for
10 min and treated with 1 µM propidium iodide (PI; Invitrogen) in 2×
SSC buffer for 10 min followed by a washing step with PBS.
Subsequently, cells were ﬁxed with 4% (w/v) paraformaldehyde
(Merck) for 30 min at room temperature, washed twice with PBS, and
permeabilizedwith PBS containing 0.2% (v/v) TritonX-100 for 15 min.
Blocking was performed in the presence of 3% (w/v) BSA in PBS for
20 min at room temperature. Primary polyclonal antibody against
active caspase 3 (Abcam) diluted in 3% (w/v) BSA in PBS was
incubated with the cells at 4 °C overnight. Cells were washed three
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anti-rabbit Alexa Fluor® 488-conjugated antibody (Invitrogen) for 2 h
at room temperature. Afterwashing, cellsweremountedwithMowiol.
Viable, apoptotic (Hoechst- and active caspase 3-positive), and
necrotic (Hoechst- and PI-positive) cell nuclei were scored under a
ﬂuorescence Axiophot microscope (Carl Zeiss) at excitation wave-
length ranges of 365±12 nm(Hoechst), 450–490 nm (Alexa Fluor®
488), and 530–585 nm (PI). Between 100 and 500 cell nuclei of three
independent experiments were counted in three distinct and
randomly selected areas per cover slip using the NIS-elements AR
3.0 ® software. Data are presented as percentage of control set 100%.
2.6.3. Cell viability assay
To estimate the number of viable cells surviving the 6-OHDA
treatment without or with a subsequent 48 h recovery period in
complete NBM medium thereafter, primary neuronal cells were
cultured in 96 well plates and analyzed with the ﬂuori- and
colorimetric CellTiter-Blue® Cell Viability Assay (Promega, Madison,
WI, USA) applying manufacturer's protocol. The assay uses the
indicator dye resazurin to measure the metabolic capacity of cells,
an indicator of cell viability. Viable cells retain the ability to reduce
resazurin into resoruﬁn, which is highly ﬂuorescent. Nonviable cells
rapidly lose metabolic activity, are not able to reduce the indicator
dye, and therefore do not generate a ﬂuorescent signal. The CellTiter-
Blue® Reagent was added to cells seeded in a 96 well plate and
incubated at 37 °C for 1 h. The ﬂuorescence emission at 590 nm was
recorded at an excitation wavelength of 560 nm in a microplate
reader (Victor, 1420 Multilabel Counter, Perkin Wallac GmbH,
Freiburg, Germany). Cells lysed with 2% (v/v) Triton X-100 in PBS
served as negative control. Data are given as percentage of control set
100%.
2.7. Reverse transcription
Total RNA was isolated from treated cells and untreated controls
using PeqGold RNA pure (PeqLab, Erlangen, Germany) according to
manufacturer's protocol. RNA concentration was measured photo-
metrically using BioPhotometer (Eppendorf). RNA integrity was
tested randomly by 1% (w/v) agarose denaturing gel electrophoresis
and ethidium bromide staining and visualized under UV-illumination.
First strand complementary DNA (cDNA) was synthesized from 1 µg
total RNA. In brief, total RNA dissolved in 14 µl diethyl pyrocarbonate-
(DEPC-) H2O was pre-incubated at 95 °C for 5 min and placed
immediately on ice. Subsequently, the reaction buffer consisting of
8 U/μl SuperScript™ III Reverse Transcriptase, 4 mM dithiotreitol,
40 mM Tris–HCl, 60 mM KCl, and 2.4 mM MgCl2, and 0.4 mM each
dNTP (Roti-mix®PCR3, Roth, Karlsruhe, Germany) was added to RNA
giving a ﬁnal volume of 25 µl. After incubation for 40 min at 55 °C,
reverse transcription was stopped by heat-inactivating the enzyme at
70 °C for 20 min. Addition of water instead of RNA served as negative
control. Transcripts of 18S ribosomal RNA (18S rRNA) served for
normalization of samples, whereas the housekeeping gene hypoxan-
thine guanine phosphoribosyl transferase (Hprt), spanning over
intron–exon borders, served as control for RNA purity.
2.8. Quantitative real time-PCR analysis
Quantitative real time PCR (qRT-PCR) analysis of catalytic and
regulatory subunits of respiratory chain complexes was performed
using SYBR® Green technology and carried out on the iQ5 detection
system (Bio-Rad, Munich, Germany). Forward and reverse primers for
speciﬁc ampliﬁcation of mitochondria-encoded subunits of the res-
piratory chain complexes ND1 (complex I; 5'-TTTACGAGCCGTAGC
CCAAA-3' and 5'-GGCCGGCTGCGTATTCTAC-3'), cytB (complex III; 5'-
ACGAAAAACACACCCATTATTT-3' and 5'-CCGTTTGCGTGTATATA
TCGGATT-3'), cox2 (complex IV; 5'-AACCGAGTCGTTCTGCCAAT-3'and 5'-AACCCTGGTCGGTTTGATGTT-3'), and ATP6 (complex V; 5'-
AGCAGTCCGGCTTACAGCTAA-3 ' and 5'-GGAGGGTGAATA
CGTAGGCTTG-3') and of nucleus-encoded complex IV subunits
cox4i1 (5'-TATGCTTTCCCCACTTACGC-3' and 5'-GCCCACAACTGTCTTC-
CATT-3') and cox4i2 (5'-AGATGAACCATCGCTCCAAC-3' and 5'-
ATGGGGTTGCTCTTCATGTC-3') were designed eliminating the possi-
bility of amplifying genomic DNA. For each set of primers, a basic local
alignment search tool (BLAST, NCBI) search revealed that sequence
homology was obtained speciﬁcally for the target gene. Standard and
sample cDNA obtained after reverse transcription were diluted 1:10
and added to a solution containing 5 µM primers and IQ SYBR Green
Supermix (Bio-Rad) consisting of 25 U/ml iTaq polymerase, 50 mM
KCl, 20 mM Tris–HCl, 0.2 mM each dNTP, 3 mM MgCl2, SYBR Green I
and stabilizers. The qRT-PCR protocol was composed of an initial
denaturation step for 10 min at 95 °C followed by 40 cycles consisting
of 10 s at 95 °C, 30 s at the appropriate for the target gene annealing
temperature (53 °C—ND1, cytB, cox2, ATP6; 60 °C—cox4i1, 18S rRNA;
65 °C—cox4i2; 61 °C—Hprt), 30 s at 72 °C, and 10 s at 78 °C. To obtain
melting curves for the resulting PCR products, a ﬁnal step was added
to the qRT-PCR consisting of 81 cycles of increasing temperature from
55 °C to 81 °C by 0.5 °C for 10 s each step. The PCR products were
quantiﬁed using the relative ΔCt method. Relative quantiﬁcation
relates the PCR signal of the target transcript to that of 18S rRNA in
treatedwith respect to untreated cells, thereby serving as endogenous
control in the validation experiments. With respect to reports about
housekeeping genes being regulated under experimental conditions,
we used Hprt as an additional control verifying the data obtained for
18S rRNA. A test for an approximately equal efﬁciency of target
ampliﬁcation was performed by looking at ΔCt value variations with
template dilutions. The absolute value of the slope of log input
amounts versus ΔCt should be approximately−3.3 and the efﬁciency
approximately 100%. The validation experiments passed this test. The
results are expressed as an average of triplicate samples of at least
three independent experiments for control and treated cells.2.9. Western blot analysis
For immunoblotting, primary mesencephalic cultures were rinsed
in PBS and subsequently lysed in ice-cold hypotonic RIPA buffer
consisting of 50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1% (v/v) Nonidet
P-40 (Sigma, Igepal, CA), and protease inhibitor cocktail (Complete
Mini, Roche, Mannheim, Germany). After centrifugation for 20 min at
13000g and 4 °C, the supernatant was collected and protein
concentration was determined by applying the BCA™ Protein Assay
Kit (Pierce, Bonn, Germany) according to manufacturer's protocol,
where BSA served as standard. Protein samples (30 µg per lane) were
loaded onto and separated by 12.5% (v/v) discontinuous sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto a Hybond™ ECL™ nitrocellulose membrane (Amer-
sham Biosciences, Buckinghamshire, UK) using Trans-Blot® SD Semi-
Dry Electrophoretic Transfer Cell (Bio-Rad). An equal loading of
samples and complete protein transfer were checked by staining of
gels and blots with Coomassie blue and Ponceau-S, respectively.
Unspeciﬁc binding sites on the membrane were blocked for 1 h with
5% (w/v) non-fat dry milk in TBST buffer consisting of 20 mM Tris, pH
7.6, 150 mM NaCl, and 0.1% (v/v) Tween 20. The nitrocellulose
membrane was then incubated for 40 h at 4 °C with monoclonal anti-
COX IV-1 antibody (MitoSciences, Eugene, OR, USA), monoclonal anti-
COX IV-2 antibody (Abnova, Heidelberg, Germany), or polyclonal anti-
β-actin antibody (Sigma-Aldrich) in TBST buffer containing 5% (w/v)
non-fat dry milk. Protein detection was performed with peroxidase-
conjugated goat anti-rabbit (Sigma-Aldrich) or rabbit anti-mouse
secondary antibody (Abcam). Peroxidase activity was visualized using
enhanced chemiluminescence, ECL™ method (Amersham Bios-
ciences). For semi-quantitative evaluation of protein expression,
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signals measured in the same blot.
2.10. ATP assay
The intracellular ATP content of neuronswas determined using the
ATP Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany)
according to the instruction of the manufacturer. In detail, 6-OHDA-
treated and untreated control cells were resuspended in an equal
amount of cell lysis reagent and dilution buffer. After centrifugation
for 5 min at 12000g at 4 °C (Eppendorf 5417R, Hamburg, Germany),
supernatants were transferred into a microtiter plate (Dynex, West
Sussex, UK) and an equal amount of luciferase reagent was added. The
luminescent reaction during absorbance/illumination at 562 nm was
analyzed immediately in a microplate reader (Victor, 1420 Multilabel
Counter, Perkin Wallac GmbH, Freiburg, Germany). The ATP content
of the 6-OHDA-treated cells was normalized to protein content by
applying the BCA™ Protein Assay Kit (Pierce) and calculated with
respect to untreated controls set 100%.
2.11. Intracellular reactive oxygen species detection
Primary neurons were cultured in 96-well plates at a density of
5×104 cells/well. After treatment with or without 6-OHDA for 24 h,
cells were loaded with 10 µM 6-carboxy-2',7'-dichlorodihydroﬂuor-
escein diacetate, di(acetoxymethyl ester) (H2DCFDA AM; Invitrogen)
diluted in PBS buffer and incubated for 45 min at 37 °C. H2DCFDA AM
is able to penetrate cells due to the acetoxymethyl ester which is
hydrolyzed by intracellular esterases to form 2',7'-dichloroﬂuorescein
(DCFH). Oxidation of DCFH by hydrogen peroxide and hydroxyl
radicals yields a highly ﬂuorescent product, 2',7'-dichloroﬂuorescein
(DCF). The ﬂuorescence intensity of DCF after excitation of the
samples at a wavelength of 485 nm was measured at an emission
wavelength of 535 nm using a ﬂuorescence microplate reader (Tecan
GENios, Crailsheim, Germany). The ﬂuorescence intensities were
normalized to the number of viable cells calculated by applying the
LDH assay and compared to control samples set 1.
2.12. Statistical analysis
Data are presented as mean±SEM of at least three independent
experiments. For statistical analysis, data were analyzed by applying
ANOVA followed by a posthoc two-tailed, independent Student's t test
applying the software SPSS (Chicago, IL, USA). Values compared to con-
trols (*) and a comparison of female vs. male values (#)were regarded as
statistically signiﬁcant at ***/###pb0.001, **/##pb0.01, */#pb0.05.
3. Results
3.1. Mesencephalic neurons from male mice showed a higher
vulnerability than those from female mice
Primary neuronal cultures from mouse brain mesencephali
(gestation day 16) consisted of mainly NeuN-immunoreactive cells.
In Fig. 1, a representative mesencephalic neuronal culture labeled
with Hoechst 33342 for cell nuclei (Fig. 1C) and stained for NeuN
(Fig. 1B) are presented. The majority of cells (≥90%) represented
neurons visualized by co-staining of more than 90% of cell nuclei with
a neuronal marker NeuN (Fig. 1A–C). Hoechst-stained, but not NeuN-
stained non-neuronal elements including astrocytes were only
marginally present. Merged pictures of Hoechst-stained nuclei with
NeuN and tyrosine hydroxylase (TH)-immunostained dopaminergic
neurons revealed less than 5% TH-positive neurons (Fig. 1D) of the
total number of neurons (Fig. 1A).
Neuron cultures were treated with the mitochondrial toxin 6-
OHDA in a time- and concentration-dependent manner. The mostcommonly applied concentration of 6-OHDA falls in the rangebetween
10 and 50 µM. Accordingly,we observed half-maximal increases of cell
death rates in the neuronal population which account for an
approximately two- to four-fold increase after treatment with 25
and 50 µM 6-OHDA for 24 h compared to untreated control cells
(Figs. 2, 3; additional data not shown). A predominance of neuronal
apoptosis compared with necrosis became obvious in cells of both
genders after treatment with 25 and 50 µM 6-OHDA for 24 h (Fig. 2A–
C). Staining of untreated mesencephalic neurons of both genders
revealed approximately 5% of apoptotic and 10% of necrotic cells with
the total cell number set 100%. Under control conditions, apoptotic and
necrotic cell death rates were both regardless of the gender. However,
a gender-speciﬁcity was detected after treatment of cells with the
mitochondrial toxin. Female andmale mesencephalic neurons treated
with 50 µM 6-OHDA exhibited an approximately 3- and 4-fold
increase of apoptotic cell death rates, respectively (Fig. 2A). Necrotic
cell death rates of female and male cells treated with the same
concentration of 6-OHDA were increased by approximately 2- and 4-
fold, respectively (Fig. 2B). Overall, male neurons exhibited an
approximately 1.5- to 2-fold higher number of apoptotic and necrotic
cells than female cells.
The LDH assay, a measure of total (apoptotic and necrotic) cell
death, performed on mesencephalic neuron cultures treated with
50 µM 6-OHDA for 24 h also revealed a higher vulnerability of male vs.
female neurons (Fig. 3A), whereas the 6-OHDA-mediated decrease of
metabolic capacity measured with the CellTiter-Blue® Cell Viability
Assay demonstrated no signiﬁcant gender-speciﬁc differences
(Fig. 3B). After treatment of neurons with 6-OHDA, cells were able
to an only partial recovery of metabolic capacity/cell viability when
incubated for additional 48 h in complete NBM medium after toxin
exposure (Fig. 3B).
3.2. Neuronal vulnerability was reﬂected by reduction of neurite length
and number of dopaminergic and non-dopaminergic cells
Additionally to a decreased number of viable cells (Fig. 3C–E, F/G,
I/J), the application of 6-OHDA caused concentration-dependent
morphological changes. Besides the degradation of cell bodies,
equivalent to the degree of cell loss, a prominent reduction and/or
shortening of neurites (Fig. 3I–K) compared to untreated cells
(Fig. 3F–H) were detected by high-resolution confocal microscopy.
Staining of mesencephalic neurons against TH and with neuroﬁla-
ment-speciﬁc antibodies (SMI 311/SMI 312) showed a punctured
structure of neurites of dopaminergic (Fig. 3J, red) and non-
dopaminergic neurons (Fig. 3K, green), respectively, when treated
with 50 µM 6-OHDA. The punctured structure and shortening of TH-
and SMI-immunoreactive neurites were considered as a qualitative
marker of neurite destruction. These changes were more pronounced
in male than in female cell cultures (data not shown). In untreated
culture, dopaminergic and non-dopaminergic neurons exhibited a
highly developed net of TH- and neuroﬁlament-immunostained
processes (Fig. 3G, H), whereas neurons treated with 50 µM 6-
OHDA showed a considerable loss of neuroﬁlament and neurites
(Fig. 3J, K). To semi-quantitatively evaluate the destruction of
neuronal processes the density of total ﬂuorescence (green and red
for non-dopaminergic and dopaminergic processes, respectively) was
measured in three confocal pictures from three different experiments.
Preliminary data revealed that approximately 70% of neuronal non-
dopaminergic processes were degraded, whereas TH-positive neurons
showed an up to 90% loss of neurites.
3.3. Gene transcription of mitochondria- and nucleus-encoded subunits
of respiratory chain complexes was decreased by 6-OHDA
Themitochondrial toxin 6-OHDA applied at 50 µM for 24 h induced
a signiﬁcant down-regulation of transcription levels of representative
Fig. 1. Immunocytochemical staining of primary mesencephalic neuron culture showed≥90% neuronal and less than 5% TH-positive neuronal immunoreactivity. The purity of
primary neuron cultures from mouse brain mesencephali was analyzed after Hoechst-staining of cell nuclei (C) by immunocytochemical staining against NeuN (B) and TH
(D) visualized after labelling with Alexa Fluor® 488 and Alexa Fluor® 594, respectively. A representative merged picture (A) of Hoechst-stained nuclei (blue) with NeuN- (green)
and TH-(red) immunostained cells revealed highly puriﬁed neuron cultures with non-neuronal impurities to an extent of less than 10% (bars 500 µm). The number of TH-positive
neurons (D) did not exceed 5% (A).
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plexes (Fig. 4A): ND1 (NADH-ubiquinone oxidoreductase, complex I,
EC 1.6.5.3.), cytB (ubiquinol-cytochrome c-reductase, complex III, EC
1.10.2.2), and ATP6 (ATP synthase, complex V, EC 3.6.3.14.). Quanti-
tative real time-PCR (qRT-PCR) analysis revealed a more pronounced
down-regulation of ND1 and ATP6 transcript levels in male than in
female cell cultures, whereas cytB was decreased in both genders to
the same extent. Transcription levels of cytochrome c oxidase (COX,
complex IV, EC 1.9.3.1.) subunit cox2 remained unchanged and did not
reveal any gender speciﬁcity. With respect to the high regulatory
potential of COX, we tested the transcription level of one of the
regulatory and nucleus-encoded enzyme subunits, COX subunit IV.
This subunit is expressed in two isoforms (COX IV-1 and COX IV-2).
The isoform COX IV-1 is known to be sensitive to the cellular energy
level, whereas COX IV-2 is unable to detect the ATP levels. Therefore,
COX IV-1 and IV-2 expression levels are of special interest. Similar
basal transcription levels of cox4i1 and cox4i2 under normal culturing
conditions were demonstrated for female and male mesencephalic
neurons, whereas signiﬁcant changes in the transcription pattern
occurred after treatment with 6-OHDA. The transcription level of
cox4i1 remained unchanged, but cox4i2 transcription was decreased
by approximately 70% (Fig. 4B). Western blot analysis of COX IV-1 and
COX IV-2 subunit isoforms in neuronal lysates supported the results of
the transcription analysis. It demonstrated a 6-OHDA-induced down-
regulation of COX IV-2 in female and male cells, whereas COX IV-1
protein remained unchanged relative to β-actin used as control
(Fig. 4C). Interestingly, the protein, but not the transcript expression of
COX IV-1 revealed approximately 3-fold higher levels in control cells
from male than female cells.Fig. 2.Mesencephalic neurons frommales showed a higher vulnerability to 6-OHDA than ne
neurons (black columns) were incubated with 25 µM and 50 µM 6-OHDA for 24 h. Apoptoti
(red), respectively (C). Viable, apoptotic, and necrotic cells were distinguished by the appe
(between 100 and 500 cells in three distinct and randomly selected areas per cover slip o
apoptotic/necrotic cell numbers compared to control conditions set 1. Signiﬁcant gender-sp
concentrations of 6-OHDA except for necrotic cell death rates at 25 µM 6-OHDA. Data repre3.4. Intracellular ATP and ROS levels were increased in a gender-speciﬁc
manner upon 6-OHDA treatment
To estimate if a decrease of respiratory chain subunits would affect
neuronal vulnerability by inﬂuencing mitochondrial energy produc-
tion, the intracellular ATP level was assessed. Surprisingly, treatment
of neurons with 50 µM 6-OHDA for 24 h caused an elevation of
intracellular ATP by approximately 50% in females and 20% in male
neurons (Fig. 5A). The observed ATP levels were higher in female than
male cells. As cells with a high level of ATP are generally assumed to be
protected from degenerative processes we analyzed the oxidative
stress as a possible reason of the 6-OHDA-mediated increased cell
death. We observed that the increase in ATP was accompanied by an
approximately 30% and 60% elevation of ROS in female and male
neuron cultures, respectively (Fig. 5B). This in turn could account for
the gender-speciﬁc elevated apoptotic and necrotic cell death in
mesencephalic neuron cultures (Figs. 2, 5C).
3.5. Estrogen exerted a neuroprotective effect on 6-OHDA-induced
elevated ROS levels and cell survival
The differences between female and male cultures were reﬂected
by a predominance of male vs. female neurons undergoing 6-OHDA-
induced cell death. This suggests an involvement of gender-speciﬁc
steroid hormones in the survivability of these cells. We therefore
studied the effect of estrogen (E, 17β-estradiol) on 6-OHDA-treated
mesencephalic neurons. E known for its wide range of protective
functions has been applied prior to and in parallel with 6-OHDA to
female and male neuron cultures (Fig. 5A–C). Although a change inurons from females. Primary cultures of female (grey columns) and male mesencephalic
c (A) and necrotic cells (B) were counted by caspase 3- (green) and PI-positive staining
arance of Hoechst-stained nuclei (blue, C). The number of apoptotic and necrotic cells
f three independent experiments) was calculated and expressed as x-fold increase of
eciﬁc differences (#) were observed for apoptotic and necrotic cell death rates at both
sent mean±SEM (**/##pb0.01, ***pb0.001, n=8).
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signiﬁcantly down-regulated in cultures from both genders (Fig. 5B).
Exhibiting a gender-speciﬁc effect, the ROS level in female cultures
reached basal level, whereas in male cultures, it showed a remaining
elevation of ROS above control cell level. Although the ROS levels
reached after 6-OHDA treatment differ in male and female cells, E
decreased the ROS levels to the same extent in neurons of both
genders. A co-treatment of E with 6-OHDA alone did not improve cell
survival, whereas a pre-treatment of cells with 100 nM E for 3 h
before the co-treatment of E with the toxin for 24 h increased the
neuron survival by approximately 5% in female and 15% in male cell
cultures (Fig. 5C). The cell viability was signiﬁcantly elevated by the E
treatment although cell death rates were still approximately 2-fold
increased compared with control levels (Figs. 5C, 3A).
4. Discussion
Mesencephalic neuron cultures aremainly comprised of cells other
than dopaminergic neurons. Accordingly, our neuron cultures showed
the presence of approximately 5% TH-positive cells among more than
90% neuronal cells (Fig. 1). The neurotoxin 6-OHDA competes with
the dopamine uptake via the plasma membrane transporter and
should therefore be speciﬁc for dopaminergic neurons, thus the
smaller percentage of cells in the culture [18]. However, the toxin also
impairs the survivability of non-dopaminergic neurons [19]. The low
number of dopaminergic/TH-immunoreactive neurons in our cell
culture system, but the high percentage of cells undergoing apoptosis
and necrosis after treatment with 6-OHDA suggest dopaminergic and
non-dopaminergic neurons being affected by 6-OHDA alike (Fig. 2).
We applied 6-OHDA at a concentration and time range (50 µM for
24 h) that are commonly used for in vitro toxicity experiments
reaching half-maximal effects on cell death rates (Figs. 2, 3) [19].
We detected predominantly apoptotic cell death in 6-OHDA-
treated mesencephalic neurons, although necrotic cell death was also
found (Fig. 2B). A number of in vitro and in vivo studies have suggested
that 6-OHDA triggers death of mesencephalic/dopaminergic neurons
via apoptosis [19,20]. Whereas necrotic cell death is mostly associated
with ATP loss, a less severe dysfunction of mitochondria with a
constant or marginally diminished ATP level initiates apoptosis [21].
Surprisingly, 6-OHDA induced an increase instead of the expected
decrease of ATP levels in mesencephalic neuron cultures (Fig. 5A)
which could, however, explain the higher rates of apoptosis compared
with necrosis (Fig. 2). Nevertheless, mitochondrial oxidative phos-
phorylation is essential for neurons to meet their high ATP demand.
Therefore, neuronal viability is imperiled when this ATP production is
even transiently diminished. Generally, in addition to bioenergetic
crisis, mitochondrial impairment also produces a concomitant
increase in ROS production, which seems to be the primary reason
for cell death occurring in our experiments (Fig. 5B).
Mitochondria represent both a target for cell death and a source for
cytotoxic oxygen radicals. Accordingly to previous reports, 6-OHDA
generates bursts of ROS by blocking complex I [19]. This is consistent
withour results (Fig. 5B) anddata fromRamsayandSinger [22] showing
that partial ubiquinone oxidation resulting from MPP+ blockade of
complex I can lead to superoxide formation in submitochondrialFig. 3. Gender-speciﬁc vulnerability of mesencephalic neurons upon 6-OHDA treatment w
neurons with 50 µM 6-OHDA for 24 h caused a three- to four-fold increased LDH release wh
columns). (B) The metabolic capacity measured with the CellTiter-Blue® Cell Viability Assay
viability of toxin-treated neurons was not signiﬁcantly improved by a subsequent 48 h recov
compared with cells in total (dead and viable cells) set 100%. The cell viability assay shows t
Data represent mean±SEM (*/#pb0.05, ***pb0.001, n=7). (C–K) Neuron cultures were sta
(green; C–E; bars 20 µm) or Pan- and axonal neuroﬁlament SMI 311 and SMI 312 to highligh
confocal z-images taken as a stack to be able to track neurites in full length in the cell mon
viable cells, equivalent to an increased number of apoptotic and necrotic cell nuclei (blue; D
non-dopaminergic neurons (I–K; bars 100 µm) compared to untreated neurons (F–H).particles. During further toxin exposure the accelerated mitochondrial
radical production impedes oxidative phosphorylation via inactivation
of Fe-S clusters within the respiratory chain. Furthermore, 6-OHDA
causes alterations inmembranepermeability, a decline inmitochondrial
membrane potential, and calcium inﬂux akin to excitotoxic cell death
processes. Such amodelwould predict superoxide production and a loss
of ATP [23]. Our data of increased ROS (Fig. 5B), secondary to complex I
inhibition, and increased apoptosis rates (Fig. 2A) support this, except
for the increased ATP levels we observed (Fig. 5A).
The sources of ATP rising under these conditions above control
levels could be eithermitochondrial and/or glycolytic. An inhibition of
glycolysis by application of deoxyglucose together with blocking the
ATPase by oligomycin and inhibiting COXby cyanide caused decreased
ATP levels in control cells indicating that anaerobic glycolytic aswell as
oxidative mitochondrial energy production are both involved in the
ATP increase (data not shown).
Unlike increased ATP levels decreased transcript levels of
representative mitochondria-encoded, catalytic subunits of the
respiratory chain complexes I, III, and V were found (Fig. 4A) which
should additionally lead to decreased respiratory chain activity
besides its blockade at complex I by 6-OHDA. In favor of decreased
mitochondrial transcript levels in PD are observations where muta-
tions or other variations in mitochondrial DNA have been implicated
in the development of PD [24]. An impaired mitochondrial DNA
transcription by ablation of the mitochondrial transcription factor A
(TFAM) in nigrostriatal dopaminergic neurons caused a progressive
loss of dopaminergic neurons due to reduced mitochondrial DNA
expression and respiratory chain deﬁciency [25]. We suggest that the
observed increased ATP levels represent an early phase of 6-OHDA
toxicity, where ATP levels are additionally supported by glycolytically
derived ATP and which would lead to the expected loss of ATP at a
later stage of toxin exposure. Supporting this idea, we considered that
although the transcript levels were decreased, the protein levels may
still be maintained to fulﬁll proper mitochondrial energy production
in the absence of themitochondrial toxin. Supportingly, the half-life of
mitochondrial proteins is equal to approximately three days [26].
Thus, although mitochondrial transcription levels are decreased,
protein levels are apparently preserved for the duration of 6-OHDA
treatment.
Furthermore, most of the respiratory chain complexes do have a
higher capacity than the activity they show under normal conditions.
The lowest excess capacity was proposed for COX thereby being the
rate-limiting enzyme of the respiratory chain [27]. Thus, if COX
subunits were down-regulated, an immediate effect on the respira-
tory chain activity should be expected. However, the transcription
levels of neither the mitochondria-encoded cox2 (Fig. 4A) nor the
nucleus-encoded cox4i1 were signiﬁcantly decreased (Fig. 4B), a
prerequisite of guaranteed maximal COX activity. Since the other
respiratory chain complexes are apparently expressed at excess
capacity, their expression should be down-regulated until this reserve
is depleted to inﬂuence the overall respiratory chain activity.
COX is the sole enzyme of the respiratory chain known to be
regulated by allosteric factors, such as ATP binding in exchange for
ADP to the inner mitochondrial domain of COX subunit IV-1 [28–30].
This enables the enzyme to detect the ATP level and adjust COX andas accompanied by a shortening of neurites of TH-positive neurons. (A) Treatment of
ich was signiﬁcantly higher in male (black columns) than in female cell cultures (grey
in cells treated with 50 µM 6-OHDA demonstrated no gender-speciﬁc differences. The
ery period in complete NBMmedium. The percentage of dead cells in the LDH assay was
he percentage of viable cells compared with untreated control cells referred to as 100%.
ined with Hoechst for cell nuclei (blue), and immunostained against TH (red), and NeuN
t neuronal processes (green; H, K). The pictures represent an overlay of 10 consecutive
olayer. (F, I) Phase contrast pictures are shown. Additionally to a decreased number of
, E, J), the application of 6-OHDA caused a destruction of neurites of dopaminergic and
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Fig. 4. 6-OHDA induced decreased transcription levels of mitochondria-encoded catalytic subunits of respiratory chain complexes and a down-regulation of nucleus-encoded cox4i2
transcripts. Primary female (grey columns) and male neurons (black columns) in culture were incubated in the presence of 50 µM 6-OHDA for 24 h. Total RNA was isolated and ﬁrst
strand cDNA was synthesized. A qRT-PCR was performed and PCR products were analyzed using the relative ΔCt method. The PCR signals of ND1, cytB, cox2, ATP6 (A) and cox4i1,
cox4i2 transcripts (B) were normalized to 18S rRNA and compared with untreated control cells referred to as 100%. Data represent mean±SEM (*/#pb0.05, **pb0.01, ***pb0.001,
n=7). In (C), Western blot analysis of COX IV-1 and COX IV-2 of neuronal lysates supports the results of transcription studies by demonstrating a 6-OHDA-induced down-regulation
of COX IV-2 in female and male cells, whereas COX IV-1 protein remained unchanged relative to β-actin used as control (C).
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expression of nuclear-encoded subunit isoforms provides a basis for
ﬁne-tuning the COX activity in response to speciﬁc metabolic needs in
different cell types and tissues. Previously, we have shown a cell type-
speciﬁc expression of COX subunit IV isoforms in the brain [31]. The
ubiquitously expressed COX isoform IV-1 renders astrocytes able to
detect neuronal energy demand and to adjust oxidative energy
metabolism to provide neurons with the energy substrate lactate
accordingly to the neuron-glia metabolic cooperation [33]. However,
meeting the high energy demand of neurons another isoform of COX
subunit IV, COX IV-2, is expressed in neurons. The isoform COX IV-2
exhibits a higher catalytic activity than COX IV-1 at the expense of an
abolished sensitivity of the enzyme towards the cellular energy level
[31,32]. In mesencephalic neurons, the transcript and protein
expression levels are higher for COX IV-2 than COX IV-1 (transcription
data not shown). The presence of COX IV-1 and COX IV-2 enables
these neurons to catalyze the enzyme reaction at maximal activity
plus being able to sensitize the cellular energy level. Treatment of
mesencephalic neurons with 6-OHDA caused a decrease of cox4i2
transcription (Fig. 4B) and COX IV-2 protein levels (Fig. 4C), whereas
cox4i1 transcription and COX IV-1 protein expression remained
unchanged (Fig. 4B), thereby constraining maximal COX activity.
Amaintained oxidative energy production by the respiratory chain
during complex I inhibition could, at least in part, be explained by
electron entry via complex II. A recent study by Folbergrová and
colleagues [34] demonstrated that complex I inhibition was not
accompanied by impaired ATP production, which was apparently due
to excess capacity of complex I documented by energy thresholds.
Thus, elevated ROS production seems to be the major reason for cell
death inmesencephalic neuron cultures. Neurons whichwere kept for
an additional period of 48 h in complete NBMmedium after 24 h of 6-
OHDA treatment did not reveal any signiﬁcant signs of cell recovery
indicating that the toxin-treated cells reached the “point of no return”on their cell death pathway (Fig. 3B). A longer exposure to 6-OHDA or
a higher toxin concentration could promote the ATP loss at a later
stage and further increase cell death [35]. ATP depletion had also been
ruled out as a cause of selective neurotoxicity of rotenone in rodents
[36]. Another study that casts doubt upon the generally accepted
notion that complex I is the primary mechanism of toxicity of PD-
linked neurotoxins employs the rotenone toxicity rat model com-
bined with a viral delivery of an alternative NADH dehydrogenase
(Ndi1). This enzyme does not generate a proton gradient but catalyzes
NADH oxidation, thereby protecting dopaminergic neurons from cell
death and decreasing oxidative stress in these cells [37].
The increased oxidative stress due to 6-OHDA exposure caused
morphological changes of mesencephalic neurons, especially a
degradation of neurites (Fig. 3D/E, J/K). This loss of neurites affected
dopaminergic and non-dopaminergic neurons.
With respect to the gender-speciﬁcity of PD, the applied viability
assays (Figs. 2, 3) revealed a higher vulnerability ofmale comparedwith
female mesencephalic neurons. Overall, male neurons exhibited an
approximately 1.5- to 2-fold higher number of apoptotic and necrotic
cells reﬂecting the incidence of PD. The underlying mechanisms of a
higher vulnerability of male vs. female neurons could be due to higher
ROS levels and a more pronounced down-regulation of mitochondrial
gene transcription, especially the subunits ND1 and ATP6 of complex I
and V, respectively (Fig. 4A). This in turn could account for a more
diminished respiratory chain activity and subsequently lowerATP levels
in the male compared with female cells (Fig. 5).
6-OHDA apparently increases oxidative stress, in addition to its
effect on complex I. Native antioxidant supplements including reduced
glutathione, its precursor N-acetylcysteine, vitamin E, the enzyme
superoxide dismutase have all been neuroprotective in experimental
PD models [38]. Besides their antioxidant effects, an effect we also
observed in 6-OHDA-treated mesencephalic neurons (Fig. 5B), estro-
gens are sex steroids that have a plethora of effects on a wide range of
Fig. 6. Schematic illustration of interactions between toxins (TOX) and estrogen (E)
with mitochondrial genes, proteins, and function. Toxins (TOX; purple) impair
mitochondrial and nuclear gene transcription of mitochondrial respiratory chain
enzymes, thereby affecting ATP production and causing increased ROS levels which, in
turn, cause elevated cell death rates. On the contrary, estrogen (E; blue) affects the
expression of mitochondrial proteins by regulating the transcription of mitochondrial
and nuclear genes promoting mitochondrial ATP and preventing from ROS production.
Furthermore, E affects the mitochondrial membrane potential (ΔΨm) and pro- and
anti-apoptotic proteins (Bcl-2, Bcl-xL). Thus, E protects cells from apoptotic or other cell
death pathways in an estrogen receptor (ER)-dependent and -independent manner.
Fig. 5. Intracellular levels of ATP and ROS were altered after 6-OHDA treatment in
primary neuron culture in a gender-speciﬁc manner. Female (grey columns) and male
(black columns) mesencephalic neurons were analyzed regarding the intracellular ATP
(A) and ROS (B) levels. (A) The intracellular ATP levels measured by applying an ATP
bioluminescence assay kit were increased by ca. 50% in females and ca. 20% inmale cells
after 24 h of 6-OHDA treatment of primary neurons. (B) Intracellular ROS levels were
elevated by ca. 30% in female and ca. 60% in male neurons treated with 50 µM 6-OHDA.
(C) Treatment of neurons with 50 µM 6-OHDA for 24 h caused an approximately 3-fold
increased LDH release which was signiﬁcantly higher in male (black columns) than in
female cell cultures (grey columns). (A-C) Pre-treatment of cells with 100 nM 17β-
estradiol (E) for 3 h and subsequent co-application of E with 6-OHDA (6-OHDA+E) did
not affect ATP levels (A) which were increased in the presence of the toxin, but
decreased, at least in part, toxin-mediated elevated ROS levels (B; §) and cell death
(C; §). The gender-speciﬁc differences remained the same for ATP, ROS levels and cell
death as in toxin-treated cell cultures. Data were normalized to ATP and ROS levels in
control cells set 100% (*). The percentage of LDH-releasing dead cells is compared to
LDH released from cells in total by lysis set 100% (*). Data show a comparison of females
vs. males (#) and a comparison of 6-OHDA- with E-co-treated cells (§). Data represent
mean±SEM (*/#/$pb0.05, ***pb0.001, n=5).
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basis for the gender differences in PD [2]. In themature central nervous
system, this hormone has a considerable activity on neural cell
metabolism and plasticity, as documented by several studies carried
out in vivo [39] and in vitro [40]. Estrogen involvement in neuroprotec-
tion is widely accepted, although the speciﬁc molecular and cellular
mechanisms of estrogen action remain obscure.
Estrogens are considered neurotrophic for dopaminergic neurons of
the nigrostriatal system promoting the growth of TH-positive neurites,
increasingTHexpression in theneonatemousemidbrain and enhancingdifferentiation and survival of dopaminergic neurons derived from
human neonatal stem cells [41–48]. Additionally, in in vitro and in vivo
models of PD, estrogen protects dopaminergic cells from toxic
compounds, such as 6-OHDA [49] and MPP+ [50]. A schematic illus-
tration (Fig. 6) summarizes protective estrogen effects onmitochondria,
particularly interactions between E and/or estrogen receptors and
mitochondrial genes, proteins, and function. Estrogen affects the
expression of mitochondrial proteins by regulating transcription of
mitochondrial and nuclear genes which are followed by increased
respiratory chain activity [51–56] and protection of cells from oxidative
stress and (apoptotic) cell death [57–61]. Here, we show that E
counteracts 6-OHDA-induced increase of ROS levels thereby decreasing
cell death rates ofmesencephalicneurons (Fig. 5C).However,wedidnot
observe any gender-speciﬁc effect of E on 6-OHDA-treated male vs.
femalemesencephalic neurons. This indicates that the protective effects
of E occur due to rather locally in the brain synthesized hormone instead
of thehormone that is systemically distributed andprovided to the cells.
Although dopaminergic neurons are the most affected by 6-OHDA
and in PD cell type, this disorder involves also non-dopaminergic
neurons [16] as also observedhere.Moreover, an impairmentof function
and survival of non-dopaminergic neurons in the mesencephalon could
additionally by still unknown mechanisms exert negative effects on
dopaminergic neurons, e.g. by releasing toxic factors such as ROS.While
mitochondrial impairment can be a consequence as well as a primary
cause of PD,mitochondrial dysfunction is clearly involved in progressive
neuronal death of dopaminergic and non-dopaminergic neurons in PD
and as such holds the promise as a potential target for the development
of new therapeutic strategies of this, currently incurable, disease.
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